急性髓系白血病缓解时体细胞突变清除与复发风险的关系
该研究纳入131例接受强化诱导化疗并在第30天达到形态学完全缓解(CR)的初治急性髓系白血病(AML)患者,对治疗前和CR时骨髓进行靶向捕获DNA测序,分析突变清除(MC)与无事件生存、总生存(OS)和累积复发率(CIR)的关系。结果显示,MC1.0(残留突变VAF<1%)和完全突变清除(CMC,无可检测残留突变)与显著更好的OS和更低的CIR相关,而MC2.5(VAF<2.5%)与上述结局无显著差异;多变量分析中CMC患者无事件生存(HR 0.43)、OS(HR 0.47)和CIR(HR 0.27)均显著优于无CMC者。结论认为CR时体细胞突变清除(尤其非白血病前基因)与更好生存和更低复发风险相关。
要点
- MC1.0和CMC与显著更好的OS和更低的CIR相关,MC2.5与上述结局无显著差异。
- 多变量分析中CMC患者无事件生存HR 0.43、OS HR 0.47、CIR HR 0.27,均优于无CMC者。
- 去除DNMT3A、TET2、ASXL1等白血病前突变后,上述预后关联更强。
核心结论
- CR时体细胞突变清除,尤其非白血病前基因突变清除,与显著更好的生存和更低复发风险相关。
- 非白血病前基因的体细胞突变可能作为AML的分子微小残留病标志物。
研究设计与样本
- 研究纳入131例既往未治疗、接受强化诱导化疗并在第30天达到形态学完全缓解(CR)的急性髓系白血病(AML)患者。
- 对治疗前和CR时骨髓采用靶向捕获DNA测序,分析突变清除(MC)与无事件生存、总生存(OS)和累积复发率(CIR)的关联。
主要发现
- MC1.0组 vs 非MC1.0组:2年OS 75% vs 61%(P = .0465),2年CIR 26% vs 46%(P = .0349)。
- CMC组 vs 非CMC组:2年OS 77% vs 60%(P = .0303),2年CIR 24% vs 46%(P = .03)。
- MC2.5与非MC2.5相比,上述结局均无显著差异。
- 多变量分析(校正年龄、细胞遗传学风险、异基因干细胞移植和流式细胞术微小残留病)显示,CMC患者较无CMC者无事件生存HR 0.43(P = .0083)、OS HR 0.47(P = .04)、CIR HR 0.27(P < .001)。
- 去除DNMT3A、TET2、ASXL1等白血病前突变后,上述预后关联更强。
关键数值与推荐
- MC1.0定义为残留突变VAF < 1%。
- CMC定义为无可检测残留突变。
- MC2.5定义为残留突变VAF < 2.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone marrow were analyzed using targeted capture DNA sequencing. We analyzed the association between mutation clearance (MC) on the basis of variant allele frequency (VAF) at CR (MC2.5: if the VAF of residual mutations was < 2.5%; MC1.0: if the VAF was < 1%; and complete MC [CMC]: if no detectable residual mutations) and event-free survival, overall survival (OS), and cumulative incidence of relapse (CIR). Results MC1.0 and CMC were associated with significantly better OS (2-year OS: 75% v 61% in MC1.0 v non-MC1.0; P = .0465; 2-year OS: 77% v 60% in CMC v non-CMC; P = .0303) and lower CIR (2-year CIR: 26% v 46% in MC1.0 v non-MC 1.0; P = .0349; 2 year-CIR: 24% v 46% in CMC v non-CMC; P = .03), whereas there was no significant difference in any of the above outcomes by MC2.5. Multivariable analysis adjusting for age, cytogenetic risk, allogeneic stem-cell transplantation, and flow cytometry-based minimal residual disease revealed that patients with CMC had significantly better event-free survival (hazard ratio [HR], 0.43; P = .0083), OS (HR, 0.47; P = .04), and CIR (HR, 0.27; P < .001) than did patients without CMC. These prognostic associations were stronger when preleukemic mutations, such as DNMT3A, TET2, and ASXL1, were removed from the analysis. Conclusion Clearance of somatic mutation at CR, particularly in nonpreleukemic genes, was associated with significantly better survival and less risk of relapse. Somatic mutations in nonpreleukemic genes may function as a molecular minimal residual disease marker in AML.
引用
- Morita K, Kantarjian HM, Wang F, et al. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018. PMID: 29702001. doi:10.1200/JCO.2017.77.6757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。